Примери за използване на Combination with cyclophosphamide на Английски и техните преводи на Български
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Computer
Busulfan in combination with cyclophosphamide.
The recommended dose of Busilvex is 0.8 mg per kg of body weight, in combination with cyclophosphamide.
Busilvex in combination with cyclophosphamide.
In new-born infants, children and adolescents,Busilvex is used in combination with cyclophosphamide or melphalan.
Busilvex in combination with cyclophosphamide In adults.
Adverse reactions from pooled study results of three randomised Phase III clinical trials of Myocet as a single agent and in combination with Cyclophosphamide(CPA).
Busulfan in combination with cyclophosphamide or melphalan.
The third study compared the effects of Myocet with epirubicin(another anthracycline anticancer medicine), both in combination with cyclophosphamide in 160 women.
In adults Busilvex is used in combination with cyclophosphamide or fludarabine.
Busilvex in combination with cyclophosphamide or melphalan has been studied in patients, mainly with blood cancer, who needed transplantation of haematopoietic progenitor cells.
In adults Busilvex is used in combination with cyclophosphamide.
Corticosteroids in combination with cyclophosphamide are the mainstay of the induction treatment for childhood GPA/MPA.
In adults Busulfan Fresenius Kabi is used in combination with cyclophosphamide or fludarabine.
Busilvex in combination with cyclophosphamide or melphalan In adults.
Therefore, the Committee decided that Myocet' s benefits are greater than its risks, in combination with cyclophosphamide, for the first-line treatment of metastatic breast cancer in women.
Myocet, in combination with cyclophosphamide, is used for the first-line treatment of metastatic breast cancer in women.
The recommended dose of Busulfan Fresenius Kabi in combination with cyclophosphamide or melphalan is based on your body weight varying between 0.8 and 1.2 mg/kg.
When used in combination with cyclophosphamide or melphalan the recommended dose of Busilvex in adults is 0.8 mg per kilogram body weight.
In the first study, 43% of the patients receiving Myocet orstandard doxorubicin in combination with cyclophosphamide responded to treatment, while in the study of Myocet or standard doxorubicin alone, 26% of each group responded.
When Busilvex was given in combination with cyclophosphamide or melphalan, all adults and children achieved myeloablation.
Clinical trials in adults Documentation of the safety andefficacy of Busilvex in combination with cyclophosphamide in the BuCy2 regimen prior to conventional allogeneic and/ or autologous HPCT derive from two clinical trials(OMC-BUS-4 and OMC-BUS-3).
When Myocet is administered in combination with cyclophosphamide the generally recommended dose is 60-75 mg/ m2.
The recommended dose of Busilvex in combination with cyclophosphamide or melphalan is based on your body weight varying between 0.8 and 1.2 mg/kg.
Dosage When Myocet is administered in combination with cyclophosphamide(600 mg/ m2) the initial recommended dose of Myocet is 60-75 mg/ m2 every three weeks.
In the third study,46% of the patients taking Myocet in combination with cyclophosphamide responded to treatment, compared with 39% of those receiving epirubicin in combination with cyclophosphamide.
Documentation on the safety andefficacy of busulfan in combination with cyclophosphamide in the BuCy2 regimen prior to conventional allogeneic and/or autologous HPCT derives from two clinical trials(OMC-BUS-4 and OMC-BUS-3).
Documentation of the safety andefficacy of busulfan in combination with cyclophosphamide in the BuCy4 or with melphalan in the BuMel regimen prior to conventional allogeneic and/or autologous HPCT derives from clinical trial F60002 IN 101 G0.